6533b85afe1ef96bd12b89c2
RESEARCH PRODUCT
The New Era of Hepatitis C
Marina BerenguerEster Coelho Littlesubject
Hepatitismedicine.medical_specialtyCirrhosisHepatologybusiness.industryHepatitis C virusHepatitis C030230 surgerymedicine.diseasemedicine.disease_causeVirologyGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineHepatocellular carcinomaToxicitymedicine030211 gastroenterology & hepatologyLiver functionbusinessdescription
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease in both Europe and the United States and is the most common reason for liver transplant. In the absence of antiviral therapy, recurrent infection is the norm with subsequent graft hepatitis and impaired survival. Whether it may be better to postpone therapy in patients in whom higher risk of failure and toxicity is coupled with lower chance of liver function improvement likely depends on several factors, including waiting time, center allocation policy, presence of hepatocellular carcinoma and local prevalence of anti-HCV-positive donors.
year | journal | country | edition | language |
---|---|---|---|---|
2017-05-01 | Clinics in Liver Disease |